Sphere Medical’s Proxima Generation 2 has met its primary endpoint in a multicentre clinical trial conducted at two UK hospitals, Queen Elizabeth Hospital Birmingham and West Suffolk Hospital.

The Proxima system is an arterial blood analyser based on Sphere Medical’s proprietary microanalyser platform technology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The primary endpoint of the study has evaluated the similar performance to laboratory and point-of-care blood-gas analysers, measuring arterial blood in a clinical setting.

The device provides real-time analysis of a patient’s arterial blood with laboratory accuracy.

Output data being displayed on a bedside monitor.

The company claims that the Proxima blood analyser can be useable for repeated blood measurements without a deterioration in performance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sphere Medical CEO Stuart Hendry said the Proxima will deliver rapid and convenient measurement of blood chemistry in a critical care setting.